ライフサイエンスコーパス: neurotensin

1 ounts from the dorsomedial SCN (vasopressin, neurotensin).

2 a high charge state (e.g., triply protonated neurotensin).

3 rotonated neurotensin, and triply protonated neurotensin.

4 Met- and Leu-enkephalin, angiotensin I, and neurotensin.

5 re not detected including neuropeptide Y and neurotensin.

6 ides: [Lsy(8)] vasopressin, substance P, and neurotensin.

7 binding in the presence of excess unlabeled neurotensin.

8 f of the neuropeptide Y cells do not contain neurotensin.

9 erminal side of proline, for substance P and neurotensin.

10 to show a normal antinociceptive response to neurotensin.

11 izing mutations bound to the peptide agonist neurotensin.

12 ive oil-induced secretion of GLP-1, PYY, and neurotensin.

13 rosine kinases and required local release of neurotensin.

14 ith wakefulness such as orexin, histamine or neurotensin.

15 rats, virally mediated overexpression of the neurotensin 1 (NT1) receptor in the nucleus accumbens an

16 omotes inflammation and colon cancer via the neurotensin-1 receptor (NTR1).

17 In addition, we also tested PD149163, a neurotensin-1 receptor agonist, which has been shown to

18 to endocytic vesicles with agonist-activated neurotensin-1 receptor, oxytocin receptor, angiotensin I

19 -[2-(4-(18)F-fluorobenzamido)ethyl]maleimide-neurotensin ((18)F-FBEM-NT).

20 ide) or a VIP receptor antagonist (hybrid of neurotensin 6-11 and VIP 7-28).

21 NT69L, is a novel neurotensin (8-13) analog that participates in the modul

22 NT69L is a novel neurotensin (8-13) analog that produces atypical antipsy

23 Neurotensin(8-13) and two related analogues were used as

24 NT69L, an analog of neurotensin(8-13), acts like an atypical antipsychotic d

25 ng peptide receptor ligands (angiotensin II, neurotensin(8-13), an analogue of the C-terminal pentape

26 s; namely, [Tyr(1)]-leu-enkephalin, [Tyr(4)]-neurotensin(8-13), and [Tyr(3)]-octreotide, each of whic

27 A set of neurotensin[8-13] (NT[8-13]) analogues featuring substit

28 le hydrogens, whereas the +1 charge state of neurotensin (9-13) has 12 exchangeable hydrogens.

29 The b 2 portion of neurotensin (9-13) has 6 exchangeable hydrogens, whereas

30 sing a commercially available small peptide, neurotensin (9-13; RPYIL).

31 ize different positions on others, including neurotensin, a 13-residue peptide involved in modulation

32 Neurotensin, a neuropeptide growth factor, and its two s

33 Neurotensin, a tridecapeptide, is widely distributed in

34 The findings also support a volume mode of neurotensin actions, specifically affecting excitatory t

35 tral tegmental area neurons, substance P and neurotensin activate a channel complex containing NALCN

36 Neurotensin activated Akt in HCT-116 cells; this effect

37 Neurotensin activated AKT through miR-155-mediated suppr

38 eurons and that it may be useful to consider neurotensin agonists as an adjunct in the treatment of s

39 S blood content is only ~1%-6%) and delivers neurotensin, an otherwise non-BBB-penetrant neuropeptide

40 We tested the effect of a novel neurotensin analog (NT69L), injected intra-peritoneally

41 he study was to induce mild hypothermia with neurotensin analog NT77 or external cooling in a rat mod

42 NT69L is a neurotensin analog that can be administered peripherally

43 NT69L, a neurotensin analog that crosses the blood-brain barrier,

44 We report on a novel neurotensin analog with higher selectivity to NTS2, name

45 These results suggest that PIH induced by neurotensin analogs represented by ABS-201 are promising

46 we showed that one of our brain-penetrating neurotensin analogs, NT69L, blocks nicotine-induced loco

47 We induced regulated hypothermia with a neurotensin analogue (NT77) to determine whether it coul

48 onnatural amino acid was incorporated into a neurotensin analogue using standard Fmoc-based protocols

49 the catabolism of bioactive peptides such as neurotensin and bradykinin.

50 gonadotropin-releasing hormone antagonists, neurotensin and complement C5a modulators, melanocortin-

51 up-regulated in carcinoid tumors, including neurotensin and connective tissue growth factor.

52 rginine ethyl ester (BAEE) and two peptides, neurotensin and insulin chain B.

53 Intermolecular cross-linking of neurotensin and intramolecular cross-linking of cytochro

54 levels of the dopaminergic circuit modulator neurotensin and is a member of a fold group that include

55 This study points out that neurotensin and its two specific receptors are expressed

56 (ACE) can cleave angiotensin I, bradykinin, neurotensin and many other peptide substrates in vitro.

57 endogenous neuropeptide is highly related to neurotensin and neuromedin U, which are involved in bloo

58 Another NTSR, sortilin, which is common to neurotensin and neurotrophins, was also detected as we h

59 siological (GnRH, GnRH(1-9), bradykinin, and neurotensin) and fluorimetric (MCA-PLGPDL-Dnp and orthoa

60 nt elevation of c-fos, prolonged increase of neurotensin, and early reduction followed by recovery of

61 paB-alpha (IkappaB-alpha) levels; and c-fos, neurotensin, and ferritin H expression were determined b

62 l gut-brain peptides, including substance P, neurotensin, and galanin, emerged as important mediators

63 Activation of orexin, neurotensin, and metabotropic glutamate Gq/11-linked rec

64 n 3 neuropeptide receptor systems (bombesin, neurotensin, and neuropeptide-Y) that offer high potenti

65 gulators such as atrial natriuretic peptide, neurotensin, and orexin B are also discussed.

66 y protonated gramicidin S, doubly protonated neurotensin, and triply protonated neurotensin.

67 ubstance P, corticotropin-releasing hormone, neurotensin, and vasoactive intestinal peptide; small mo

68 dulators, gamma-aminobutyric acid (GABA) and neurotensin, are shown to be present in IGL neurons.

69 We found that LHA MC4R-GFP neurons coexpress neurotensin as well as the leptin receptor but do not co

70 se include peptides, such as substance P and neurotensin, as well as acetylcholine and noradrenaline.

71 sense oligonucleotides (ASO), we synthesized neurotensin-ASO conjugates and evaluated their cellular

72 bradykinin specifically at Phe(5)-Ser(6) and neurotensin at Arg(8)-Arg(9).

73 n residues are at all four positions cleaves neurotensin at the neurolysin site, and the reverse muta

74 s increase neurotensin release from dopamine-neurotensin axons in the PFC.

75 A model for differential recognition of neurotensin based on differences in surface charge distr

76 mately 1; at higher receptor concentrations, neurotensin binding displays positive cooperativity with

77 We purified three neurotensin-bound NTR1 variants from Escherichia coli an

78 lar [Ca(2+)] induced by GPCR agonists (e.g., neurotensin, bradykinin, and angiotensin II).

79 siologically important neuropeptides such as neurotensin, bradykinin, and gonadotropin-releasing horm

80 tors were treated with fluorescently labeled neurotensin (BT-NT).

81 ed in most of the pharmacological effects of neurotensin but is associated with hypothermia and hypot

82 ACE2 can also cleave des-Arg bradykinin and neurotensin but not bradykinin or 15 other vasoactive an

83 In the lateral hypothalamus, neurotensin, but neither orexin nor MCH neurons, express

84 have discovered that the modulatory peptide neurotensin can induce a persistent synaptic depression

85 Intra-PFC administration of neurotensin concentration-dependently increased extracel

86 Neurotensin conjugation also improved the potency of mor

87 el biochemical species (human serum albumin, neurotensin, creatinine, glycine, and alanine) were reta

88 Tissue concentrations of CCK, GIP, and neurotensin decline with feeding.

89 Neurotensin decreases food intake in the rat when inject

90 rine genes: prohormone convertase 1 (PCSK1); neurotensin; delta/notch-like EGF repeat containing; and

91 with 5 mg/kg morphine (intraperitonally) or neurotensin directly into the periaqueductal gray region

92 Since neurotensin-dopamine interactions have been implicated i

93 ptor dynamics, possibly explains the reduced neurotensin efficacy in the constitutively active NTSR1

94 Neurotensin exerts potent analgesia by acting at both NT

95 ortical activity, whereas mice deficient for neurotensin exhibited increased REM sleep, implicating t

96 ere we show that ablation of a population of neurotensin-expressing neurons in the central amygdala d

97 Neurotensin expression increased colony formation by HCT

98 ing gastrin-releasing peptide, neuromedin B, neurotensin, gastrin, cholecystokinin and arginine vasop

99 se, including substance P, somatostatin, and neurotensin have actions such that they should be consid

100 The neurotensin hexapapetide fragment NT(8-13) is a potent a

101 The GABA- and neurotensin-immunoreactive neurons project to the SCN wi

102 ting less than 50 amol of angiotensin II and neurotensin in a microLC MALDI MS run under standard exp

103 ntal approaches implicating the neuropeptide neurotensin in both the mechanism of action of antipsych

104 NTS1 and behaves like the endogenous ligand neurotensin in the functional assay.

105 , these findings suggest a selective role of neurotensin in the modulation of dopamine neurotransmiss

106 high-affinity neurotensin receptor (NTR) and neurotensin in these subdivisions of rat NAc to determin

107 For triply charged neurotensin, in which a direct comparison can be made be

108 insulinotropic peptide (GIP), glucagon, and neurotensin increase by respective factors of 25-, 6-, 6

109 In mice, intraperitoneal administration of neurotensin increased the growth rate of HCT-116 xenogra

110 Cell stimulation with the GPCR agonist neurotensin induced a rapid and reversible plasma membra

111 asphyxial cardiac arrest was decreased with neurotensin-induced hypothermia (14+/-11 secs) and prolo

112 There was less ischemic neuronal damage with neurotensin-induced hypothermia (28+/-24%) and prolonged

113 fter asphyxial cardiac arrest was lower with neurotensin-induced hypothermia (score, 0) and prolonged

114 or 24 hrs (prolonged external cooling) or by neurotensin-induced hypothermia administration 30 mins a

115 Neurotensin-induced hypothermia improved neurologic outc

116 s were randomized to a normothermic control, neurotensin-induced hypothermia, brief external cooling,

117 Our results show that neurotensin-induced mast cell degranulation in colonic e

118 examined whether substance P is involved in neurotensin-induced mast cell degranulation.

119 Whereas CPA6 converts enkephalin and neurotensin into forms known to be inactive toward their

120 Infusion of neurotensin into the fourth ventricle induced NREM sleep

121 that colonic mast activation in response to neurotensin involves release of substance P.

122 Neurotensin is a tridecapeptide that participates in reg

123 Nearly all neurotensin is colocalized with neuropeptide Y in IGL ne

124 In the rat prefrontal cortex (PFC), neurotensin is exclusively localized to dopamine axons a

125 Because neurotensin is exclusively localized to dopamine axons i

126 The estimated IC(50) value (2 nM) for neurotensin is in agreement with the literature; this ag

127 alpha)q/11 upon treatment of SCLC cells with neurotensin is not inhibited by ET-18-OCH3.

128 Neurotensin is present in selective mesolimbic dopaminer

129 ulation of lateral septum neurons expressing neurotensin (LS(Nts)) in mice that are selectively tuned

130 The peptide transmitter neurotensin may be one such modulator of interneurons.

131 Neurotensin-mediated targeted delivery represents a poss

132 Neurotensin MPN, orexin-containing LHA, and catecholamin

133 RH) neurons show extensive coexpression with neurotensin mRNA, but they are distinct from hypocretin/

134 os-IR was observed in neurons that expressed neurotensin mRNA.

135 Expression of the gene encoding neurotensin/neuromedin N (NT/N) is mostly limited to the

136 Here we show that neurotensin neurons in the central nucleus of the amygda

137 her, these observations suggest that CRH and neurotensin neurons in the LHA constitute a novel anatom

138 Specific loss of SCN neurotensin neurons was associated with loss of activity

139 st robust projection of the central amygdala neurotensin neurons was to the parabrachial nucleus, a b

140 es-specific vasopressin and species-specific neurotensin neurons.

141 It was previously shown that bombesin and/or neurotensin (NT) acts as a survival and migratory factor

142 Expression of the neuropeptide neurotensin (NT) and its high affinity receptor (NTR1) i

143 The expression of neurotensin (NT) and its receptor (NTR1) is up-regulated

144 Neurotensin (NT) and neurotensin receptor 1 (NTR1) have

145 The peptide transmitter neurotensin (NT) exerts diverse neurochemical effects th

146 A method was developed to quantify neurotensin (NT) fragment [8-13] and a novel NT[8-13] de

147 minal end of the minimal biologically active neurotensin (NT) fragment, leading to the synthesis of n

148 Release of neurotensin (NT) from intestines is markedly stimulated

149 ral injections of leptin induce hypothalamic neurotensin (NT) gene expression in association with a r

150 Neurotensin (NT) has emerged as an important modulator o

151 eported elevated serum levels of the peptide neurotensin (NT) in children with autism spectrum disord

152 (PMA)-mediated secretion of the gut peptide neurotensin (NT) in the BON human endocrine cell line.

153 ANC-1 as a model system, we demonstrate that neurotensin (NT) induced a rapid and striking activation

154 ANC-1 as a model system, we demonstrate that neurotensin (NT) induced translocation of phosphorylated

155 Neurotensin (NT) is a 13 amino acid neuropeptide that is

156 Neurotensin (NT) is a 13-amino-acid peptide that, among

157 Neurotensin (NT) is a gastrointestinal neuropeptide that

158 Neurotensin (NT) is a gut peptide that plays an importan

159 Neurotensin (NT) is a gut peptide that plays an importan

160 Neurotensin (NT) is a neuropeptide neurotransmitter in t

161 Neurotensin (NT) is a neuropeptide with antinociceptive

162 Neurotensin (NT) is a tridecapeptide neurotransmitter in

163 Native neurotensin (NT) is a tridecapeptide that binds to NTR a

164 We had shown that the peptide neurotensin (NT) is increased in the serum of children w

165 The neuropeptide/hormone neurotensin (NT) mediates intestinal inflammation and ce

166 Neurotensin (NT) modulates ventral tegmental area (VTA)

167 In the Arc, a few CART neurons coexpress neurotensin (NT) mRNA.

168 transduction properties of the class A GPCR neurotensin (NT) receptor 1 (NTS1) under defined experim

169 In contrast to these receptors, the neurotensin (NT) receptor NTS1 is much less stable in de

170 The neurotensin (NT) receptor-1 (NTS1) is overexpressed in a

171 Previous studies indicated that the peptide neurotensin (NT) stimulates Cl(-) secretion in animal sm

172 Application of the modulatory peptide neurotensin (NT) to midbrain dopaminergic neurons transi

173 Neurotensin (NT) triggers signaling in human colonic epi

174 Neurotensin (NT) via its receptor 1 (NTR1) modulates the

175 Neurotensin (NT), a gut hormone and neuropeptide, increa

176 eviously reported that high levels of plasma neurotensin (NT), a gut hormone released from enteroendo

177 Neurotensin (NT), a neuropeptide released in the gastroi

178 (CALR), gastrin releasing peptide (GRP), and neurotensin (NT), and receive input from the retina and

179 the present study, we identify the effect of neurotensin (NT), one of the most abundant peptides in t

180 own to be secreted by NE-like cells, such as neurotensin (NT), parathyroid hormone-related peptide, s

181 ng corticotropin-releasing hormone (CRH) and neurotensin (NT), secreted in response to the metabolic

182 recombinant IL-37 (1 to 100 ng/mL) inhibits neurotensin (NT)-stimulated secretion and gene expressio

183 that focus on receptors for the neuropeptide neurotensin (NT).

184 ts effect being nearly comparable to that of neurotensin (NT).

185 cholecystokinin (CCK), peptide YY (PYY), and neurotensin (NT)] and on glucose, lipid, and bile acid m

186 Neurotensin (NT; also known as NTS), a 13-amino-acid pep

187 ed peptides containing the sequence of human neurotensin, NT4, are much more selective than native mo

188 ecific binding of ligands, arrays presenting neurotensin (NTR1), adrenergic (beta1), and dopamine (D1

189 abinoid (CB(1)) antagonist (SR141716), and a neurotensin (NTS(1)) antagonist (SR48692).

190 es of the IL-8 functional network identified neurotensin (NTS) and CXCL1 to be preferentially express

191 red and characterized the functional role of neurotensin (NTS) in cell line and animal models of CRPC

192 Neurotensin (NTS) is a 13 amino acid neuropeptide that i

193 Neurotensin (NTS) is a 13-amino-acid peptide that functi

194 alamic area (LH) expressing the neuropeptide neurotensin (Nts) is critical for orchestrating sleep-wa

195 d cecum, as well as preproglucagon (Gcg) and neurotensin (Nts) mRNA expression in the cecum, increase

196 s promote food and water consumption but LHA neurotensin (Nts) neurons preferentially induce water in

197 c LHA leptin receptor (LepRb)-containing and neurotensin (Nts)-containing (LepRb(Nts)) neurons lie in

198 Here, we show that neurotensin (NTS)-expressing glutamatergic neurons in th

199 e we identify a steroid-responsive subset of neurotensin (Nts)-expressing mPOA neurons that interface

200 a thalamo-amygdala pathway, both expressing neurotensin (NTS).

201 of bivalent ligands for dopamine D2 receptor/neurotensin NTS1 receptor (D2R/NTS1R) heterodimers.

202 However, the effects of neurotensin on cortical interneurons are poorly understo

203 itive binding assay with BT-NT and unlabeled neurotensin on NTR1 arrays.

204 and downstream signaling, whether induced by neurotensin or ionizing radiation, establish a molecular

205 2-adrenergic compounds, but not cannabinoid, neurotensin, or muscarinic drugs.

206 Thiolated neurotensin peptide (Cys-NT) efficiently reacted with (1

207 nd to specifically target pancreatic cancer, neurotensin peptide (NT)-conjugated polyethylene glycol

208 We identified a modified neurotensin peptide capable of improving the cellular up

209 Thiolated neurotensin peptide was then labeled with (18)F using th

210 a simple and efficient method to radiolabel neurotensin peptide with (18)F for NTR-targeted imaging.

211 We conclude that neurotensin plays a key role in the pathogenesis of C. d

212 axons in the PFC, we also determined whether neurotensin plays a role in the ability of dopamine agon

213 These findings suggest that neurotensin plays an important role in regulating prefro

214 releasing hormone, galanin, neuropeptide Y, neurotensin, preproenkephalin and tachykinin 1; this inv

215 d that neurons positive for the neuropeptide neurotensin promote NREM sleep.

216 Neurotensin promotes inflammation and colon cancer via t

217 roscopic immunolabeling of the high-affinity neurotensin receptor (NTR) and neurotensin in these subd

218 The prevalence of neurotensin receptor (NTR) in several human tumors makes

219 The type 1 neurotensin receptor (NTS1) belongs to the G protein-cou

220 re of a constitutively active, agonist-bound neurotensin receptor (NTSR1) and molecular dynamics simu

221 groups were inherently detrimental to human neurotensin receptor 1 (hNTR1) binding affinity or recep

222 peutic efficacy of oAd/DCN/LRP-PEG-NT toward neurotensin receptor 1 (NTR)-overexpressing pancreatic c

223 cally induced hypothermia (PIH) by the novel neurotensin receptor 1 (NTR1) agonist ABS-201 in a focal

224 mbinations that preferentially interact with neurotensin receptor 1 (NTR1) and our stabilized mutants

225 2-carboxylic acid (SR48692), a high-affinity neurotensin receptor 1 (NTR1) antagonist.

226 Using neurotensin receptor 1 (NTR1) as a proof of principle, w

227 In this study, we define the high-affinity neurotensin receptor 1 (NTR1) as a tractable new molecul

228 Increased expression of neurotensin receptor 1 (NTR1) has been shown in a large

229 Neurotensin (NT) and neurotensin receptor 1 (NTR1) have been shown to play a

230 Neurotensin receptor 1 (NTR1) is a G protein coupled rec

231 Neurotensin receptor 1 (NTR1) is overexpressed in ductal

232 tivating the G protein-coupled receptor, the neurotensin receptor 1 (NTR1).

233 Small molecule neurotensin receptor 1 (NTSR1) agonists have been pursue

234 gnaling leading to NED through activation of neurotensin receptor 1 (NTSR1) and neurotensin receptor

235 quired for this network disturbance, we used neurotensin receptor 1 (Ntsr1) cre-driver mice to ablate

236 on microscopy structure of full-length human neurotensin receptor 1 (NTSR1) in complex with truncated

237 Neurotensin receptor 1 (NTSR1) is a G-protein-coupled re

238 Neurotensin receptor 1 (NTSR1) is overexpressed in most

239 STR1, SSTR2), kisspeptin recepotor (KissR1), neurotensin receptor 1 (NTSR1), neuropeptide S receptor

240 ese effects requires mast cell expression of neurotensin receptor 1 and neurolysin.

241 Starting from the rat neurotensin receptor 1, a class A GPCR, we generated a s

242 receptors (angiotensin II type 1A receptor, neurotensin receptor 1, vasopressin V2 receptor, thyrotr

243 and neurotensin receptor 3 (NTSR3), but not neurotensin receptor 2 (NTSR2).

244 Pharmacological manipulation of neurotensin receptor 2 confirms behavioural effects obse

245 acrophage inflammatory protein 1 (MIP-1) and neurotensin receptor 2.

246 vation of neurotensin receptor 1 (NTSR1) and neurotensin receptor 3 (NTSR3), but not neurotensin rece

247 te as to whether a peripherally administered neurotensin receptor agonist represents a sound strategy

248 ta further support a role for NT69L or other neurotensin receptor agonists to treat nicotine addictio

249 eadministration of a mu opioid receptor or a neurotensin receptor antagonist into the ventral PAG.

250 administered peripherally, serum levels and neurotensin receptor binding potency of 1 peaked within

251 The neurotensin receptor ligand (111)In/(177)Lu-3B-227 has d

252 Slosky et al. report a beta-arrestin-biased neurotensin receptor ligand that may curtail drug abuse

253 l and hydrodynamic experiments that purified neurotensin receptor NTS1, a class A GPCR, dimerizes in

254 We previously determined the structure of neurotensin receptor NTSR1 in an active-like conformatio

255 and a hormone through the activation of the neurotensin receptor NTSR1, a G-protein-coupled receptor

256 (AS-MOR MM), antisense PNAs targeted to the neurotensin receptor subtype 1 (AS-NTR1), or saline and

257 Compounds acting via the neurotensin receptor type 2 (NTS2) are known to be activ

258 cosylated Thr10 contulakin-G for a number of neurotensin receptor types including the human neurotens

259 Neurotensin receptor was expressed in 88% of the surgica

260 Neurotensin receptor-1 (NTR1) is a promising target for

261 on by binding of its high affinity receptor, neurotensin receptor-1 (NTR1).

262 ding only to microspots corresponding to the neurotensin receptor; this specificity was further demon

263 Accumulating evidence suggests that neurotensin receptors (NTRs) play key roles in cancer gr

264 Compounds active at neurotensin receptors (NTS1 and NTS2) exert analgesic ef

265 Compound 1 binds to human neurotensin receptors 1 and 2 with IC(50) of 10.6 and 54

266 tained high affinity and agonist potency for neurotensin receptors and exhibited dramatically improve

267 wo new tritiated tracers for angiotensin and neurotensin receptors are described.

268 Neurotensin receptors have been implicated in a wide var

269 Ca2+ mobilization mediated by neurotensin receptors is also inhibited by ET-18-OCH3.

270 ither the protein phosphatase calcineurin or neurotensin receptors, and persists surprisingly long af

271 opeptide growth factor, and its two specific neurotensin receptors, NTSR1 and NTSR2, were shown to be

272 pitates with G(alpha)q/11 upon activation of neurotensin receptors; this association is inhibited by

273 Targets of neurotensin-regulated microRNAs were identified via bioi

274 Neurotensin regulates both satiety and breast cancer gro

275 ysis in freely moving rats to assess whether neurotensin regulates PFC GABAergic interneurons.

276 Xenin-25 is a 25-amino acid neurotensin-related peptide that amplifies GIP-mediated

277 ating that D2 autoreceptor agonists increase neurotensin release from dopamine-neurotensin axons in t

278 ption that is mediated in part by opioid and neurotensin release within the ventral PAG.

279 Peptide YY (PYY) and neurotensin responses resembled those of GLP-1.

280 Neurotensin's effects are mediated mainly through two re

281 Systematic modification of neurotensin sequence in NT4 peptides led to identificati

282 n digesting pythons, the regulatory peptides neurotensin, somatostatin, motilin, and vasoactive intes

283 Neurotensin stimulated differential expression of 38 mic

284 ed microarray analysis of mRNA expression by neurotensin-stimulated NCM460 cells that overexpressed N

285 opin-releasing hormone, nerve growth factor, neurotensin, substance P and mast cells are recruited hi

286 Larger peptides such as neurotensin, substance P, bradykinin, and the oxidized i

287 To determine the feasibility of using neurotensin to improve the productive uptake of antisens

288 The ability of neurotensin to increase GABA levels in the PFC was also

289 a novel thalamo-amygdalar circuit which uses neurotensin to initiate and sustain NREM sleep.

290 heir stress resistance and the adsorption of neurotensin to plasma membranes with the distinct biphas

291 ding of NT4 peptides, with respect to native neurotensin, to either cancer cell lines or human cancer

292 Likewise, IV dosing of TXB2-hFc fused with neurotensin (TXB2-hFc-NT) at 25 nmol/kg resulted in a ra

293 neurotensin type 1 receptor (hNTR1), the rat neurotensin type 1 and type 2 receptors, and the mouse n

294 urotensin receptor types including the human neurotensin type 1 receptor (hNTR1), the rat neurotensin

295 n (group I glutamate metabotropic receptors, neurotensin type 1) could similarly elicit wave-like act

296 n type 1 and type 2 receptors, and the mouse neurotensin type 3 receptor were determined.

297 natriuretic peptide, somatostatin, oxytocin, neurotensin, vasopressin, and substance P), and three th

298 In each region, neurotensin was detected in a few NTR-immunoreactive axo

299 Neurotensin was functional in B cell lines; it induced t

300 TSR2 was overexpressed, NTSR1 decreased, and neurotensin was unexpressed in B cell leukemia patient's

301 -dead TrkA, and siRNA against TrkA sortilin, neurotensin, whereas siRNA against p75(NTR) and the MAP

302 eptor concentrations, NTS1 binds the agonist neurotensin with a Hill slope of approximately 1; at hig

303 Fusion of nonopioid pharmacophores, such as neurotensin, with opioid ligands represents an attractiv